Tandem Diabetes Care Announces First Quarter 2026 Financial Results
Tandem Diabetes Care delivered Q1 sales of $247.2 million, up 5% year-over-year, while achieving record pump shipments and expanding gross margin to 55%. The company reported positive Adjusted EBITDA of $2.7 million, a significant improvement from a loss of $79.9 million in the prior year, driven by operational efficiency and a 0.00% convertible debt offering.
Key figures
- Revenue
- 247221000
- Guidance
- 2026 sales $1.065B-$1.085B; gross margin 56%-57%; Adjusted EBITDA margin 5%-6%
- Revenue Yoy
- 5%
- Fcf
- 4786000
- Gross margin
- 55%
- Gross profit
- 136788000
- Pump shipments
- 29000
- Adjusted ebitda
- 2730000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.